Important Identified Risks

Introduction

Important Identified Risks are one of the three categories of safety concerns used within the Safety Specification of a Risk Management Plan (RMP). They represent risks for which adequate evidence supports a causal association with the medicinal product and which are considered important for ongoing risk management activities.

Although the concept appears straightforward, classification is frequently challenging in practice. Regulatory expectations require clear scientific justification and a direct line-of-sight from evidence to classification, to planned pharmacovigilance activities and to proportionate risk minimisation measures. This article provides practical classification tools, a comparative table of safety concern categories, sample RMP wording and operational guidance to improve inspection-readiness and governance.

Regulatory Definition

An Important Identified Risk is:

An undesirable clinical outcome for which adequate evidence supports an association with the medicinal product and which is important for risk management purposes.

The definition comprises two distinct elements:

• Identified — sufficient evidence supports a causal association with the product.
• Important — the risk warrants ongoing attention because of clinical seriousness, frequency, preventability, impact on benefit–risk, public health implications or the need for additional risk-minimisation or pharmacovigilance activities.

If either element is absent, the risk should not be classified as an Important Identified Risk.

Relevant regulatory context: - EMA GVP Module V — Risk Management Systems (principal EU guidance). - EMA Risk Management Plan template and annexes. - Commission Implementing Regulation (EU) No 520/2012 and other EU pharmacovigilance legislation. - ICH E2E and comparable international guidance for pharmacovigilance planning. - National competent authorities may have inspection expectations consistent with GVP and national legislation.

Identified vs Important — Evidence and Decision Making

What "Identified" means - Evidence sources: clinical trials, post-marketing spontaneous reports, pharmacoepidemiology, registries, scientific literature, regulatory assessments, and validated signals. - Level of evidence: consistent temporal association, plausible biological mechanism, dechallenge/rechallenge data, strength of association in epidemiology, dose-response, and exclusion of alternative explanations strengthen an identified classification. - Documentation requirement: a concise evidence summary and reference list must be maintained in the RMP evidence repository and be readily retrievable for inspection.

What "Important" means - Importance is evaluated independently of causality and reflects the need for management. - Typical criteria: seriousness (e.g., life-threatening, permanent disability), frequency (high absolute incidence or high relative risk), public health impact (large exposed population), preventability (if action can reduce risk), reversible vs irreversible outcomes, impact on the product's benefit–risk, and feasibility of risk minimisation. - Regulatory expectation: justification of importance with context (indication, population, duration of use) and quantification where possible.

Practical Classification Checklist (Operational)

Use this checklist when assessing whether to classify a safety concern as an Important Identified Risk. Document responses and supporting evidence in the RMP rationale section.

For each candidate risk, answer the following:

1. Evidence of causality (Identified)
2. Is there clinical or epidemiological evidence suggesting a causal relationship? (Yes/No)
3. Is the evidence peer-reviewed or documented in regulatory assessments or signal validation? (Yes/No)
4. Are alternative explanations (disease, concomitant drugs) adequately considered and addressed? (Yes/No)

5. Supporting evidence references and brief summary: [link/quote]

6. Clinical seriousness (Important)

7. Does the event cause death, life-threatening consequences, hospitalisation, persistent/significant disability, congenital anomaly, or require intervention to prevent such outcomes? (Yes/No)

8. Is the event associated with long-term morbidity? (Yes/No)

9. Frequency and magnitude

10. What is the estimated frequency (absolute incidence or reporting rate)? [value/source]

11. Does the frequency or relative risk materially affect the benefit–risk at the population level? (Yes/No)

12. Public health impact and exposure

13. What is the size of the exposed population? [estimate]

14. Is the product likely to be widely used in vulnerable populations (pregnant women, elderly, children)? (Yes/No)

15. Preventability and manageability

16. Are there effective risk minimisation measures available that could reduce occurrence or severity? (Yes/No)

17. Would routine pharmacovigilance suffice, or are additional measures required? (Routine / Additional PV / RMMs)

18. Impact on benefit–risk

19. Would the presence of this risk materially alter the benefit–risk ratio for the approved indication(s)? (Yes/No)

20. If yes, describe impact and thresholds considered.

21. Regulatory precedent and label status

22. Is the risk already included in the SmPC/label as a warning/contraindication? (Yes/No)

23. Have regulators identified this as a key risk in prior assessments? (Yes/No)

24. Feasibility and proportionality

25. Can the risk be monitored and mitigated in routine care? (Yes/No)

26. Are proposed RMMs proportional to the risk’s severity and frequency? (Yes/No)

27. Decision

28. Classify as: Important Identified Risk / Identified but not important / Potential Risk / Missing Information
29. Rationale: concise justification (2–4 sentences) referencing the checklist items and evidence.

Operational notes: - Require sign-off by the RMP owner and QPPV (or delegated safety governance committee). - Store completed checklists in the RMP evidence repository and index them to the RMP version control. - Use quantitative thresholds where possible (e.g., absolute risk >1/100; relative risk >2 in robust studies), but align thresholds with product-specific context and regulatory expectations. - For borderline cases, document alternative options considered and the rationale for the final decision.

Comparative Table: Safety Concern Categories and Sample RMP Wording

The following table contrasts the three safety concern categories used in the Safety Specification and provides concise sample RMP wording to enhance inspection-readiness and operational use.

Notes on table use: - Sample wording is intentionally concise and structured to be copy-paste ready into an RMP; expand in the evidence and activities annexes. - Link each sample wording to document references (clinical study IDs, PSUR sections, signal assessment numbers) within the RMP.

Sample Detailed RMP Wording for an Important Identified Risk (Template)

Use a consistent template for each Important Identified Risk in the RMP. This format aligns with inspection expectations for clarity and traceability.

• Title: Important Identified Risk — [short name of event]
• Rationale for inclusion:
• Evidence summary (2–4 sentences; include study identifiers, number of cases, key findings).
• Regulatory precedent (if any).
• Risk characterisation:
• Frequency (estimate and source).
• Severity and clinical course.
• Time to onset.
• Reversibility.
• Known or suspected risk factors.
• At-risk populations.
• Impact on benefit–risk:
• Describe potential effect on use in approved indication(s).
• Planned routine pharmacovigilance:
• Specific activities (e.g., enhanced spontaneous reporting, case series analysis).
• Timelines and milestones.
• Planned additional pharmacovigilance (if any):
• Study design and objectives (e.g., retrospective cohort to estimate incidence; pregnancy registry with planned enrolment).
• Expected deliverables and timelines (protocol submission, interim analyses, final report).
• Planned or implemented risk minimisation measures:
• Modality (SmPC change, educational materials, monitoring requirements).
• Target audience (prescribers, pharmacists, patients).
• Implementation and effectiveness metrics.
• Triggers for reclassification or removal:
• Predefined evidence thresholds or regulatory agreement.
• Responsibility and governance:
• RMP owner, study sponsors, QPPV oversight, and safety governance committee roles.
• Last reviewed and next review due.

Example (abbreviated): Important Identified Risk — Severe hypersensitivity (anaphylaxis) - Rationale: Ten confirmed anaphylaxis cases temporally associated with product administration in phase 3 trials; positive dechallenge in 6 cases; no alternative explanation in most cases. - Characterisation: Incidence 0.05% (clinical trials); onset typically within 30 minutes; can be life-threatening; requires emergency treatment. - Planned PV: Routine PV, enhanced case validation process, and aggregated periodic review every 3 months for first 2 years post-authorisation. - RMMs: SmPC contraindication in patients with prior anaphylaxis to product components; prescribing information to include management algorithm; healthcare professional (HCP) letter and training for rapid recognition and management; monitoring of RMM effectiveness via selected indicators (HCP awareness survey, reporting rates). - Governance: RMP owner — Head of PV; QPPV to oversee; Safety Steering Committee to review quarterly. - Review triggers: New epidemiological data indicating incidence ≤ background risk with high certainty or regulator-directed changes.

Implementation Details and Operationalisation

Integration into processes - Link RMP classification to signal management SOPs: every validated signal should trigger a classification checklist review and, if applicable, a documented update to the RMP. - Integrate RMP checklists into electronic safety databases or document management systems with mandatory fields and version control. - Ensure traceability: cross-reference RMP entries with signal assessment documents, PSUR/PBRER chapters, study protocols and final reports, and label changes.

Documentation and evidence repository - Maintain an evidence repository for each Important Identified Risk containing raw data (redacted where necessary), study reports, literature extracts, signal assessment reports, and meeting minutes. - Index repository content in the RMP with hyperlinks or clear references for quick retrieval during inspections.

Templates and standard wording - Use standardised templates for RMP entries and for the "rationale" section to reduce variability and ensure all regulatory expectations are addressed. - Ensure sample RMP wording is succinct but contains links to the full evidence and study plans.

Metrics and effectiveness evaluation - Define measurable indicators for risk minimisation effectiveness (e.g., monitoring adherence rates, lab monitoring uptake, reduction in event incidence). - Establish data sources and reporting cadence (quarterly/annually) for these indicators.

Decision-making timelines - For post-authorisation situations, define expected timelines for additional studies (e.g., protocol within X months, interim analysis by Y months) and record them in the RMP. - Use predefined decision points to determine whether further action (e.g., RMM changes, label updates) is needed.

Governance and Roles

Key governance elements to support robust Important Identified Risk classification and management:

• RMP Owner: Responsible for preparation, maintenance and version control of the RMP. Ensures alignment with PV activities and RMM implementation.
• QPPV: Oversight responsibility for the pharmacovigilance system; must be able to explain and defend Important Identified Risks and associated activities to inspectors.
• Safety Governance Committee / Benefit–Risk Committee: Multidisciplinary body (clinical, epidemiology, regulatory, safety, medical affairs, health economics) to review classification decisions, thresholds, and study plans. Minutes should document the rationale.
• Signal Review Team: Operational team responsible for initial signal detection, validation and proposing classification recommendations using the checklist.
• Clinical Risk Expert(s): Provide clinical input on seriousness, management and preventability.
• Regulatory Affairs: Ensure RMP wording and RMMs are aligned with label content and regulatory commitments.
• Document control and change management: All RMP changes must follow formal change control with approvals, versioning, and archive.

Inspection relevance: - Inspectors will expect evidence of clear roles, documented decision-making, version control, and timely execution of PV commitments. - Ensure meeting minutes explicitly record decisions about classification and link to the supporting evidence.

Inspection Readiness: What Inspectors Look For

Inspectors typically assess: - Clear scientific justification for each Important Identified Risk (evidence and rationale). - Traceability between signals, evidence, classification checklists and the RMP. - Governance records — who authorised the classification and when. - Evidence repository accessibility, indexed and retrievable within reasonable timeframes. - RMP implementation — are planned PV and RMM activities in place and functioning? Are timelines met? - Effectiveness measures — have RMMs been evaluated and is there documentation of results and follow-up actions? - Lifecycle management — records of periodic review, triggers for change and evidence supporting risk removal where applicable. - QPPV knowledge and oversight — capability to explain key RMP decisions and to demonstrate oversight mechanisms.

Practical inspection-prep checklist: - Completed classification checklists for each Important Identified Risk. - Evidence summaries (concise) plus source documents. - Decision minutes from Safety Governance Committee with attendees and actions. - Version-controlled RMP and change log. - Active study protocols and status reports for planned PV activities. - Copies of SmPC/label text that relate to the risk. - Metrics and reports showing RMM implementation and monitoring. - SOPs for signal management and RMP maintenance.

Lifecycle Management and Reclassification

Periodic review - Set scheduled reviews (e.g., annually or aligned with PBRER/PSUR submission) and ad hoc reviews triggered by new evidence. - Reclassification criteria should be predefined: e.g., substantial new evidence confirming lack of causal association; robust epidemiology demonstrating background incidence; or clinical practice changes that render a risk no longer important.

Removal - Provide a documented scientific rationale if removing an Important Identified Risk. Reviewers and signatories should include clinical and epidemiology expertise plus QPPV approval. - Update associated RMMs and SmPC language accordingly and confirm removal with regulatory authorities when required by regulatory commitments.

Common Pitfalls and How to Avoid Them (Operational Focus)

• Listing every adverse reaction: Use the checklist to filter for importance; document why less important reactions are not included.
• Weak or undocumented rationale: Store concise evidence summaries and references; require sign-off.
• Poor traceability: Use consistent identifiers linking signals, evidence, checklists and RMP entries.
• Lack of governance records: Ensure committee minutes detail the decision process.
• No measurable RMM effectiveness criteria: Define indicators at the time of RMM implementation and collect baseline data.

Key Takeaways

• Important Identified Risks require both sufficient evidence of causality and justification of importance for ongoing management; both elements must be documented.
• Use a practical classification checklist and standardised RMP wording to improve clarity, traceability and inspection-readiness.
• Maintain governance structures, evidence repositories and measurable RMM effectiveness indicators.
• Link signal management outputs directly to RMP updates and ensure the QPPV and safety governance committees can demonstrate oversight.
• Periodic lifecycle review and clearly documented reclassification/removal decisions are essential to keep the RMP focused and relevant.

References

1. EMA Good Pharmacovigilance Practices (GVP) Module V — Risk Management Systems.
2. EMA Risk Management Plan Template.
3. Commission Implementing Regulation (EU) No 520/2012.
4. Regulation (EC) No 726/2004.
5. Directive 2001/83/EC.
6. ICH E2E Pharmacovigilance Planning.
7. EMA Guidance on Safety Concerns and Risk Management Planning.